Lung cancer is one of the most common malignant tumors with the highest incidence. Gene mutations are rare in small-cell lung carcinoma (SCLC), resulting in targeted therapy being only a third-line recommendation. Surufatinib (Sulanda) is an oral angio-immune kinase inhibitor used to treat solid tumors. We report a case of SCLC treated with surufatinib combined with camrelizumab, with good therapeutic results in our department. The patient experienced over 18 months of progression-free survival and over 28 months of overall survival. This suggests that surufatinib combined with camrelizumab is an effective third-line treatment for SCLC patients. However, the response rate to surufatinib treatment in all patients with SCLC remains unknown and needs to be determined in a large population.

中文翻译：

---

索凡替尼联合卡瑞利珠单抗作为广泛期小细胞肺癌患者有价值的三线挽救疗法：病例报告和文献综述。

肺癌是最常见、发病率最高的恶性肿瘤之一。小细胞肺癌 (SCLC) 中基因突变很少见，因此靶向治疗仅是三线建议。Surufatinib (Sulanda) 是一种口服血管免疫激酶抑制剂，用于治疗实体瘤。我们科室报道一例索凡替尼联合卡瑞利珠单抗治疗SCLC的病例，取得了良好的治疗效果。患者经历了超过 18 个月的无进展生存期和超过 28 个月的总生存期。这表明索凡替尼联合卡瑞利珠单抗是 SCLC 患者有效的三线治疗方法。然而，所有 SCLC 患者对索凡替尼治疗的反应率仍不清楚，需要在大量人群中确定。